Insilica's Dr Thomas Luechtefeld argues process traceability, not benchmark accuracy alone, determines whether AI toxicology decisions can be trusted.
|Articles|April 15, 2002
- BioPharm International-04-01-2002
- Volume 15
- Issue 4
Analytical Advances: Paperless or Less Paper?
Author(s)Mary Ellen Goffredo
by Mary Ellen Goffredo, NuGenesis Technologies Corporation Weighing the Options
Advertisement
Articles in this issue
over 24 years ago
Beyond QSITover 24 years ago
Determining Protein Concentration, Part 1: Methodologyover 24 years ago
Guest Editorial: The Protein Production Challengeover 24 years ago
Business Matters: Personalized Medicine or Blockbusterology?over 24 years ago
Advances in Amino Acid AnalysisAdvertisement
Related to this article
At PharmSci 360, Insilica CEO Thomas Luechtefeld will present on auditable agentic AI systems and how they are expanding computational toxicology beyond single predictive models.
BMS's Dr Nathan Pennell outlines how biomarker testing barriers and trial diversity affect patient access to targeted oncology drugs.
Advertisement
Advertisement
Trending on BioPharm International
1
Treasury Proposes Adding Biotech to Outbound Investment Restrictions Under COINS Act
2
TaiMed’s Anti-CD4 Antibody TMB-365 Reduces HIV Viral Load in Phase 1, Supporting Long-Acting Combination Regimens
3
Gilead to Buy Oral IL-23R Peptide HCXT-2001 for $1.275 Billion
4
BioNTech, BMS to Pair Pumitamig With Trodelvy in Phase 3 First-Line TNBC Trial
5